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Open acSummary
Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuha-
lerþtiotropium (TIO) HandiHaler vs. placebo (PBO)þTIO in patients with chronic obstructive
pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting b2-agonists (ICS/
LABA).
Methods: The cost-effectiveness analysis was based on the 12-week, randomised, double-blind
CLIMB trial. The study included 659 patients with pre-bronchodilator forced expiratory volume
in 1 s  50% and 1 exacerbation requiring systemic glucocorticosteroids or antibiotics theof Thoracic Medicine, Haukeland University Hospital, Jonas Lies vei 65, N-5021 Bergen, Norway. Tel.:
ed.uib.no, nielsenrune@me.com (R. Nielsen).
3.06.007
cess under CC BY-NC-ND license.
1710 R. Nielsen et al.preceding year. Patients received BUD/FORM 320/9 mg bid þ TIO 18 mg qd or PBO bid þ TIO
18 mg qd. Effectiveness was defined as the number of severe exacerbations (hospitalisation/
emergency room visit/systemic glucocorticosteroids) avoided. A sub-analysis included antibi-
otics in the definition of an exacerbation. Resource use from CLIMB was combined with Danish
(DKK), Finnish (V), Norwegian (NOK) and Swedish (SEK) unit costs (2010). The incremental cost-
effectiveness ratios (ICERs) for BUD/FORM þ TIO vs. PBO þ TIO were estimated using descrip-
tive statistics and uncertainty around estimates using bootstrapping. Analyses were conducted
from the societal and healthcare perspectives in Denmark, Finland, Norway and Sweden.
Results: From a societal perspective, the ICER was estimated at V174/severe exacerbation
avoided in Finland while BUD/FORM þ TIO was dominant in the other countries. From the
healthcare perspective, ICERs were DKK 1580 (V212), V307 and SEK 1573 (V165) per severe
exacerbation avoided for Denmark, Finland and Sweden, respectively, while BUD/
FORM þ TIO was dominant in Norway. Including antibiotics decreased ICERs by 8e15%. Sensi-
tivity analyses showed that results were overall robust.
Conclusion: BUD/FORM þ TIO represents a clinical and economic benefit to health systems and
society for the treatment of COPD in the Nordic countries. (ClinicalTrials.gov Identifier:
NCT00496470).
ª 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Population-based studies provide evidence of high preva-
lence of chronic obstructive pulmonary disease (COPD)
within the Nordic countries, with age-dependant rates as
high as 9% in Finland, 10% in Norway, 14% in Sweden and 17%
in Denmark [1e9]. COPD entails a substantial economic
burden. For example, the total annual societal costs of COPD
in Finland in 2006 wereV194million, of whichmore than 50%
were healthcare costs [10]. A study from Sweden estimated
total costs of COPD to society at V982 million in 1999 [11].
Studies from the other Nordic countries emphasise the sub-
stantial costs related to COPD exacerbations [12e14]. In
addition, repeated acute exacerbations of COPD have been
shown to permanently affect lung function and patients’
quality of life [15e17]. Therefore, reducing exacerbations
and associated hospital admissions has been established as
an important clinical and societal goal [18,19].
Budesonide/formoterol (BUD/FORM) is a combined long-
acting b2-agonist (LABA) and inhaled corticosteroid (ICS).
When BUD/FORM twice daily (bid) was added to tiotropium
(TIO; a long-acting muscarinic antagonist) once daily (qd) in
the CLIMB trial, it significantly reduced the number of se-
vere exacerbations by 62% [20]. Here, severe exacerbations
were defined as requiring hospitalisation and/or emergency
room (ER) visit and/or use of systemic glucocorticosteroids
(GCS). An economic evaluation is required to investigate
how this reduction relates to the increased costs of main-
tenance treatment.
In a cost-effectiveness analysis (CEA), the costs and ef-
fects of one healthcare intervention relative to another are
assessed by calculating the incremental cost-effectiveness
ratio (ICER). To determine whether a treatment is cost
effective compared with an alternative, the cost per gained
unit of effectiveness (e.g., cost per exacerbation avoided)
as measured by the ICER must be compared with the
payer’s willingness to pay (WTP) for that particular gained
unit of effectiveness. If the ICER is lower than the WTP,
then the programme may be considered cost effective. A
treatment is said to be dominant when it has a betteroutcome at a lower cost than the comparator. While cost-
effectiveness studies for COPD treatments often estimate
the cost per exacerbation avoided, a WTP value for an
exacerbation avoided has not officially been agreed upon.
Instead, results may be compared to ICERs and/or WTPs
published and used in other studies, such as those by
Najafzadeh et al. (2008) [21], Oostenbrink et al. (2004) [22]
and Rutten-van Molken et al. (2007) [23].
A previous CEA of adding BUD/FORM to TIO has been
performed for healthcare perspectives in Australia, Canada
and Sweden [24], based on the clinical results from the
CLIMB trial [20]. However, due to differences in healthcare
systems, economic evaluations cannot easily be transferred
and applied across countries. Our objective was to inves-
tigate the cost effectiveness associated with triple therapy
(BUD/FORM þ TIO) relative to single therapy (placebo
[PBO]þTIO) from societal and healthcare perspectives in
Denmark, Finland, Norway and Sweden. Hence, the present
analysis builds on the methodology of the previous CEA
[24], but also includes productivity losses since authorities
in these countries also consider the societal perspective
when making decisions relating to the economic value of
healthcare treatments [25e28].Methods
Study design
Resource use and effectiveness outcomes were based on
the CLIMB study, a 12-week, randomised, double-blind,
placebo controlled, parallel-group, multicentre study [20].
Patients were recruited from outpatient clinics and the
study was conducted in 102 research sites in nine countries,
including Australia (10 sites), Canada (16), France (12),
Germany (12), Hungary (13), Poland (10), Slovakia (13),
Spain (6) and Sweden (10). The study had a sample size of
659 patients, 329 in the BUD/FORM (320/9 mg bid)þTIO
(18 mg qd) arm and 330 in the PBO þ TIO arm. Terbutaline
(TER; 0.5 mg/dose) was used as needed in both arms. All
Nordic CEA of adding ICS/LABA to LAMA in COPD 1711patients were aged 40 years, had pre-bronchodilator
forced expiratory volume in 1 s (FEV1) not exceeding 50%
of the predicted normal value and at least one exacerba-
tion requiring systemic GCS and/or antibiotics in the pre-
ceding year. Based on post-bronchodilator FEV1,
approximately 25%, 64% and 11% of patients were classified
as being Global initiative for chronic Obstructive Lung Dis-
ease (GOLD) stage II, III and IV [18], respectively. Baseline
characteristics, treatment compliance and withdrawal
rates over the trial period were comparable between the
two treatment groups. A full description of the CLIMB study
including the study design can be found in the clinical
publication [20].
Time horizon and perspectives
The time horizon for the CEA, 3 months, was based on the
duration of the CLIMB trial. The CEA considered results
from both a societal perspective (which includes both the
direct and indirect costs of COPD) and from a healthcare
perspective (taking only direct costs into account) as stip-
ulated in the Danish [25], Finnish [26], Norwegian [27] and
Swedish [28] guidelines for economic evaluations.
Effectiveness
The effectiveness measure used in the economic analysis
was the number of severe exacerbations avoided with BUD/
FORM þ TIO relative to PBO þ TIO. In the CLIMB trial, a
severe exacerbation was defined as one or more of the
following: hospitalisation, ER visit or use of systemic GCS.
Adjacent treatments were counted as one severe exacer-
bation while treatments that were at least 1 treatment-
free day apart were counted as separate severe exacer-
bations. The number of severe exacerbations avoided was
the effectiveness measure for this CEA. Antibiotic use,
where exacerbation or COPD were stated as the reason for
prescription by the investigator, was added to the definition
of a severe exacerbation in a sub-analysis, as antibiotics are
part of the exacerbation management in all countries in the
analysis [29e32].
Healthcare resource use and costs
The resource use collected in the CLIMB trial and used in
this CEA included hospitalisations (days), ER visits, BUD/
FORM Turbuhaler (Symbicort Turbuhaler 320/9 mg, bid,
per protocol), TIO HandiHaler (Spiriva HandiHaler
18 mg, qd, per protocol), TER Turbuhaler (Bricanyl
Turbuhaler 0.5 mg, as needed for rescue, actual use),
systemic GCS (days) and antibiotics (days, when antibiotics
were added to the definition of an exacerbation).
Although data on outpatient visits were not collected in
the CLIMB trial, it was assumed that a general practitioner
(GP) consultation had taken place when a patient was
treatedwith systemic GCS or antibiotics if the treatment had
not been initiated during an ER visit or a hospitalisation; if
treatment was initiated during ER or hospitalisation, it was
assumed that no GP resources were required. The first such
treatment course was assumed to be associated with a GP
visit, while any subsequent courses were assumed to beassociated with a GP call. Only one GP consultation was
applied if the patient started treatment with both systemic
GCS and antibiotics at the same date. Cost per hospital-
isation day was derived from official Diagnosis Related Group
(DRG) data. The CLIMB data did not include the type of
hospitalisation ward (intensive care unit [ICU] or general
ward [GW]). Instead, the DRG costs applied were assumed to
implicitly account for the distribution of ICU versus GW
lengths of stay (LOS) of hospitalisations. In Norway, ER
outpatient consultations rarely take place at hospitals but
rather in GP-staffed urgent care centres. This was reflected
in the relatively low unit cost of a Norwegian ER visit. For the
other countries, the cost of an ER visit was assumed to be
included in the DRG for patients hospitalised through the ER.
The cost of an ER visit was added in Norway for such patients.
Pharmaceutical costs were based on pharmacy retail
prices, excluding VAT but including any patient co-payment,
and were collected from official databases [33e36]. The
price per dose was applied to all protocol medications. For
systemic GCS and antibiotics, the price per day based on
average dose of the substance recommended by national
guidelines and/or expert opinions was applied. In particular,
the most commonly used systemic GCS was prednisolone in
all countries (which was also the most frequently prescribed
systemic GCS in the trial). Antibiotics were assumed to be
amoxicillin plus clavulanic acid (Denmark), doxycycline
(Finland and Sweden) and amoxicillin (Norway), based on
expert opinion. If two or more antibiotic courses over-
lapped, the daily cost of the most common antibiotics was
applied only once for all days of antibiotic treatment. When
systemic GCS or antibiotics were administered in a hospital
setting, drug costs were not added separately but were
assumed to be covered by the hospitalisation cost.
Productivity losses
Sick leave due to severe COPD exacerbations was modelled
in the analysis’ societal perspective although these data
were not collected within the CLIMB trial. The number of
sick-leave days was based on severe exacerbation days
from the CLIMB trial. Indirect costs were only applied to
patients who were below the official retirement age in each
country (Denmark and Sweden: 65 years, Finland: 63 years,
and Norway: 67 years) [37]. Following the human capital
approach (HCA), the national labour cost was used to
calculate the cost of each day that patients were absent
from their paid work.
Employment rates were based on the findings from a
retrospective, non-interventional, epidemiological study in
Sweden [38]. This study estimated that 36% of COPD pa-
tients in working ages (<65 years) in Sweden were full-time
or part-time gainfully employed. The employment rate for
patients with severe COPD was estimated at 22%. The same
employment rate (36% in base case) was used for all Nordic
countries and the patients were assumed to be full-time
employed.
The national annual average labour cost (including em-
ployers’ social contributions) for each country was used to
estimate the unit cost per day. [39]. Since there was no in-
formation on whether the exacerbation days occurred on
working days, the applied labour cost per day was based on
the total annual labour compensation divided by 365 days
(i.e. reflecting labour cost per day and not per working day).
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bation days. Leisure time, house work and caregivers’ pro-
ductivity losses were not considered in this analysis.
Cost estimation
The healthcare perspective included direct costs (medica-
tion use and non-medication healthcare resource use) and
the societal perspective included direct plus indirect costs
(productivity loss due to severe COPD exacerbations). Costs
were calculated by applying country-specific unit costs
from Denmark (DKK), Finland (V), Norway (NOK) and Swe-
den (SEK) to the CLIMB trial’s pooled resource use. All unit
costs were year 2010 values (except medication costs which
were collected in 2011 and not indexed) as presented in
Table 1, indexed where necessary using each country’s
price indexes from national statistics [40e42]. Official price
lists, DRG data and national databases as well as publica-
tions were used to cost hospitalisation days [43e46], ER
visits [47e50], GP consultations [47,49e52], medication
[33e36] and productivity loss [39]. Costs were not dis-
counted due to the study time horizon of <1 year. Average
annual exchange rates of year 2010 were applied to the
individual country costs (V1 Z DKK7.447, V1 Z NOK8.007
and V1 Z SEK9.541) [53e55].
Statistical methods and analyses
Mean values of the use for each resource type in each
treatment arm and the corresponding mean difference be-
tween arms were calculated with descriptive statistics based
on the full analysis set (n Z 659), consisting of the pooled
data from the CLIMB trial. All values were calculated as per
patient 3 months’ exposure by dividing the summed resource
use across patients with the summed exposure time (yieldingTable 1 Unit costs 2010 [33e36,39,43e52].
Unit costs
Denmark
DKK (V)
Healthcare costs
Hospitalisation, daya 5376 (722)
ER, visit 1000 (134)
GP, visit 197 (27)
GP, call 46 (6)
Medication costs
BUD/FORM 320/9 mg, inhalation 8.27 (1.11)
TIO 18 mg, inhalation 11.47 (1.54)
TER 0.5 mg, inhalation 0.67 (0.09)
Systemic GCS, day 5.12 (0.69)
Antibiotics, day 8.52 (1.14)
Indirect cost
Labour cost, day 1017 (137)
ER: Emergency room, GP: General practitioner, BUD/FORM: Budeson
Terbutaline Turbuhaler, GCS: Glucocorticosteroid, LOS: Length of st
a For Finland, Norway and Sweden, the cost per day was based on the
For Denmark, costs were weighted based on complicated or unc
DkDRG0425 were used. Exchange rates (V1 Z DKK7.447, V1 Z NOK8
b For Norway this cost is more accurately described as cost per ‘urg
c 50% of GP visit (expert opinion).resource use per patient per day) andmultiplied by 365.25/4.
To estimate the uncertainty around the mean difference
between treatment arms, 95% confidence intervals (CI) were
estimated with bootstrapping. Bootstrapping is a non-
parametric technique, which involves large numbers of re-
petitive computations to estimate the shape of a statistic’s
sampling distribution empirically. In this analysis, 1000
bootstrap samples, each consisting of nZ 659 observations,
were drawn with replacement from the full analysis set. For
each of the bootstrap samples and for each resource type,
the mean use in each treatment arm and the corresponding
differences between treatment arms were calculated. Thus,
the bootstrap procedure yields a distribution for each
resource type consisting of 1000 observations of the differ-
ence between treatment arms. This distribution was used to
estimate the 95% CI for that difference. The CI was estimated
as the mean difference  1.96 multiplied by the standard
deviation of the 1000 differences.
For each country, ICERs from the societal and health-
care perspectives were analysed separately, with and
without antibiotics included in the definition of a severe
exacerbation. ICERs were estimated by descriptive sta-
tistics (D mean cost/D mean severe exacerbation). To
assess the uncertainty around the ICER estimates, the ICER
was calculated for each of the bootstrap samples and the
result is presented in cost-effectiveness scatter plots. The
cost-effectiveness acceptability curves (CEACs) relate
ICER estimates to potential WTP values. For each WTP, the
CEAC shows the proportion of ICER estimates that are
lower than the WTP, i.e. the estimated probability that
BUD/FORM þ TIO is cost effective relative to PBO þ TIO
for that particular WTP to avoid a severe exacerbation.
As parameters were estimated with uncertainty, one-
way sensitivity analyses were performed to analyse theFinland Norway Sweden
V NOK (V) SEK (V)
499 5361 (670) 6005 (629)
307 341 (43)b 2416 (253)
92 283 (35) 1300 (136)
19 51 (6) 650 (68)c
1.01 6.33 (0.79) 10.00 (1.05)
1.65 10.84 (1.35) 13.81 (1.45)
0.08 0.57 (0.07) 0.81 (0.08)
0.48 5.22 (0.65) 9.78 (1.03)
0.51 9.30 (1.16) 7.60 (0.80)
116 1295 (162) 1137 (119)
ide/formoterol Turbuhaler, TIO: Tiotropium HandiHaler, TER:
ay in hospital, COPD: Chronic obstructive pulmonary disease.
average cost per stay (DRG088) and average LOS DRG088 (COPD).
omplicated exacerbations; codes DkDRG0423, DkDRG0424 and
.007 and V1 Z SEK9.541).
ent, unscheduled GP visit’.
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The exacerbation rate scenarios served two distinct pur-
poses. The first tested the effect of changing the baseline
risk of severe exacerbation in either arm and the second
changed the effectiveness of BUD/FORM in reducing that
risk. Parameters that were changed in the one-way deter-
ministic sensitivity analyses were related to:
 exacerbation rate:
B exacerbation rate in each arm  one standard devi-
ation (SD)
B exacerbations avoided between arms  one SD
 resource use given exacerbation:
B hospitalisation days in each arm  one SD
B systemic GCS days in each arm  one SD
B ER visits in each arm  one SD
B trial-based hospital LOS replaced by national
averages
B no GP consultations for systemic GCS/antibiotics
prescriptions
B no GP consultations for subsequent systemic GCS/
antibiotic prescriptions
B GP visit or GP call for all systemic GCS/antibiotics
courses
B addition of one GP (follow-up) visit or call for each
exacerbation
 resource unit costs:
B hospital unit cost  20%
B ER unit cost  20%
B ER unit cost equal to GP visit cost
 productivity losses:
B employment rate of 100% or 22%
B length of absenteeism  20%
B labour costs  10%Results
Effectiveness
In the CLIMB trial, 25 patients (7.6%) experienced at least
one severe COPD exacerbation over the treatment period inTable 2 Three-month mean severe exacerbation rate per patie
Exacerbation type BUD/FORM þ
(n Z 329)
Hospitalisation 0.02
ER (not associated with hospitalisation) 0.01
ER (any exacerbation requiring ER) 0.02
Systemic GCS 0.10
Total number of exacerbations 0.11
Antibioticsb 0.11
Total number of exacerbations
(including antibiotics)
0.13
ER: Emergency room, BUD/FORM: Budesonide/formoterol Turbuhale
interval, GCS: Glucocorticosteroid, COPD: Chronic obstructive pulmon
a Measures exacerbations avoided with BUD/FORM þ TIO relative to
b Reason for antibiotic prescription: Exacerbation or COPD. All values
calculated with descriptive statistics while the 95% CI were estimatethe BUD/FORM þ TIO group, compared with 61 patients
(18.5%) in the PBO þ TIO group [20]. In total, 0.18 (95% CI
0.09, 0.27) severe exacerbations were avoided per patient
over 3 months of BUD/FORM þ TIO treatment (Table 2).
Including antibiotics in the definition of a severe exacer-
bation increased the mean difference between treatment
arms to 0.19 (95% CI 0.09, 0.28).
Healthcare resource use
Treatment with BUD/FORM þ TIO resulted in fewer
healthcare visits, lower levels of non-protocol medication
required and a reduced amount of productivity loss
compared with PBO þ TIO (Table 3).
Costs
A summary of the direct and indirect costs and their dif-
ferences between treatment arms per patient using Danish,
Finnish, Norwegian and Swedish unit costs is presented in
Table 4 (the results from the sub-analysis including antibi-
otic use can be found in the online appendix). The major
cost driver for the BUD/FORM þ TIO group across all
countries was the total cost of medication (67.1e74.9%).
The major cost component for the PBO þ TIO group across
all countries was the total cost of healthcare visits
(41.2e47.3%), which again was mainly due to the cost of
hospitalisation days (75.4e94.7%, not shown). Direct costs
were higher with BUD/FORM þ TIO than with PBO þ TIO in
Denmark, Finland and Sweden. Total costs were lower with
BUD/FORM þ TIO in all countries except Finland (Table 4).
Incremental cost-effectiveness ratios
ICER values are presented in Table 5. From the societal
perspective, the cost per severe exacerbation avoided for
patients using BUD/FORM þ TIO versus PBO þ TIO was
estimated at V174 for Finland. BUD/FORM þ TIO was
dominant for Denmark, Norway and Sweden. In the sub-
analysis including antibiotics, the cost per severe exacer-
bation avoided was V149 for Finland; BUD/FORM þ TIO was
dominant for Denmark, Norway and Sweden.nt by treatment arm.
TIO PBO þ TIO
(n Z 330)
Mean differencea
(95% CI)
0.04 0.02 (0.01, 0.06)
0.04 0.03 (0.00, 0.05)
0.05 0.03 (0.00, 0.06)
0.27 0.17 (0.08, 0.25)
0.29 0.18 (0.09, 0.27)
0.18 0.07 (0.01, 0.14)
0.32 0.19 (0.09, 0.28)
r, TIO: Tiotropium HandiHaler, PBO: Placebo, CI: Confidence
ary disease.
PBO þ TIO.
in each treatment arm as well as differences between arms were
d with bootstrapping.
Table 3 Mean resource use and exacerbations per patient in three months.
BUD/FORMþTIO
(n Z 329)
PBO þ TIO
(n Z 330)
Mean difference (95% CI)
Healthcare visits
Hospitalisation (days) 0.10 0.31 0.21 (0.48, 0.06)
ER visits (not associated with hospitalisation) 0.01 0.04 0.03 (0.05, 0.00)
ER visits (any exacerbation requiring ER) 0.02 0.05 0.03 (0.06, 0.01)
GP visitsa
Systemic GCS prescription 0.07 0.17 0.10 (0.15, 0.05)
Systemic GCS and/or antibiotics 0.09 0.21 0.11 (0.17, 0.06)
GP callsa
Systemic GCS prescription 0.01 0.05 0.03 (0.07, 0.01)
Systemic GCS and/or antibiotics 0.02 0.06 0.04 (0.08, 0.01)
Medication
BUD/FORM (inhalations) 182.63 0 182.63
TIO (inhalations) 91.31 91.31 0
TER (inhalations) 272.93 349.17 76.24 (115, 38)
Systemic GCS (days)b 0.91 2.08 1.16 (1.88, 0.44)
Antibiotics (days) 0.77 1.39 0.61 (1.14, 0.07)
Productivity loss
<63 years: sick leave (days) 0.44 0.64 0.20 (0.61, 0.19)
<65 years: sick leave (days) 0.41 0.72 0.32 (0.68, 0.04)
<67 years: sick leave (days) 0.35 0.70 0.36 (0.68, 0.03)
Productivity loss including antibiotics
<63 years: sick leave (days) 0.51 0.72 0.21 (0.65, 0.22)
<65 years: sick leave (days) 0.49 0.82 0.33 (0.74, 0.06)
<67 years: sick leave (days) 0.44 0.80 0.36 (0.71, 0.00)
All values in each treatment arm as well as differences between arms were calculated with descriptive statistics while the 95% CI were
estimated with bootstrapping.
BUD/FORM: Budesonide/formoterol Turbuhaler, TIO: Tiotropium HandiHaler, PBO: Placebo, ER: Emergency room, GP: General
practitioner, GCS: Glucocorticosteroid, TER: Terbutaline Turbuhaler, CI: Confidence interval, CEA: Cost-effectiveness analysis.
a Systemic GCS/antibiotic treatments not initiated during hospitalisation or at an ER were assumed to be associated with GP con-
sultations (a GP visit for the first prescription and a GP call for subsequent prescriptions).
b The number of systemic GCS days in this analysis is slightly different from those presented in the previous CEA [26], as all GCS days
were included in the previous CEA regardless of when they occurred (i.e. they were also included even when occurring during
hospitalisation).
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exacerbation avoided for patients using BUD/FORM þ TIO
versus PBO þ TIO was estimated at DKK 1580 (V212), V307
and SEK 1573 (V165) in Denmark, Finland and Sweden,
respectively; BUD/FORM þ TIO was dominant for Norway. In
the sub-analysis including antibiotics, the cost per severe
exacerbation avoided was estimated to be DKK1449 (V195),
V281 and SEK1342 (V142) for Denmark, Finland and Swe-
den, respectively, and dominant for Norway. Thus, for both
perspectives, inclusion of antibiotics in the definition of a
severe exacerbation yielded results that were qualitatively
similar, although ICERs were reduced by 8e15%.
Fig. 1 presents the cost-effectiveness scatter plots
which show that BUD/FORM þ TIO was associated with
more severe exacerbations avoided for each sample real-
isation compared with PBO þ TIO. From a societal
perspective (not including antibiotics), the estimated
probabilities that BUD/FORM þ TIO was a dominant treat-
ment option (lower-right quadrant) were 50% in Denmark,
32% in Finland, 74% in Norway and 52% in Sweden. The cost-
effectiveness scatter plots for the sub-analysis where an-
tibiotics treatment is included in the definition of a severe
exacerbation can be found in the online appendix.Fig. 2 shows the CEACs for the four countries with one
diagram per country, each including four curves: healthcare
versus societal perspective, both excluding and including
antibiotics. The CEACs illustrate the relationship between
the WTP to avoid a severe exacerbation and the probability
of BUD/FORM þ TIO being cost effective compared with
PBO þ TIO. As an example, using a WTP of V600 (DKK 4468;
NOK 4804; SEK 5725) as in the previous CEA [24] yields
probabilities of BUD/FORM þ TIO being cost effective of
82%, 79%, 93% and 85% in Denmark, Finland, Norway and
Sweden, respectively, from a societal perspective,
excluding antibiotics. In addition, Fig. 2 shows that applying
the societal perspective increases the probability of BUD/
FORM þ TIO being cost effective relative to applying the
healthcare perspective. Including antibiotics in the defini-
tion of a severe exacerbation has little impact on the
probability of the treatment being cost-effective.Sensitivity analyses
Results from the one-way sensitivity analyses are presented
in tornado diagrams, which illustrate how the ICER changes
Table 4 Total costsa per patient in 3 months (2010).
Cost per patient
BUD/FORMþTIO
(n Z 329)
PBO þ TIO
(n Z 330)
Mean difference
(95% CI)
Denmark DKK (V) DKK (V) DKK
Total cost of healthcare visits 554 (74) 1727 (232) 1173 (2642, 297)
Total cost of medication 2745 (369) 1292 (173) 1453 (1423, 1483)
Total direct cost 3299 (443) 3019 (405) 280 (1219, 1779)
Total indirect cost 414 (56) 737 (99) 323 (696, 46)
Total costs 3713 (499) 3756 (504) 42 (1915, 1825)
Finland V V V
Total cost of healthcare visits 59 182 123 (269, 24)
Total cost of medication 358 180 177 (174, 181)
Total direct cost 416 362 55 (95, 204)
Total indirect cost 51 74 24 (71, 22)
Total costs 467 436 31 (166, 227)
Norway NOK (V) NOK (V) NOK
Total cost of healthcare visits 556 (69) 1716 (214) 1160 (2616, 295)
Total cost of medication 2306 (288) 1200 (150) 1106 (1080, 1132)
Total direct cost 2862 (357) 2916 (364) 54 (1536, 1427)
Total indirect cost 451 (56) 911 (114) 460 (884, 40)
Total costs 3313 (414) 3827 (478) 514 (2420, 1388)
Sweden SEK (V) SEK (V) SEK
Total cost of healthcare visits 713 (75) 2187 (229) 1474 (3227, 280)
Total cost of medication 3317 (348) 1564 (164) 1753 (1714, 1791)
Total direct cost 4030 (422) 3751 (393) 279 (1513, 2072)
Total indirect cost 463 (49) 824 (86) 361 (778, 51)
Total costs 4494 (471) 4575 (480) 82 (2291, 2122)
Exchange rates (V1Z DKK7.447, V1Z NOK8.007 and V1Z SEK9.541). All values in each treatment arm as well as differences between
arms were calculated with descriptive statistics while the 95% CI were estimated with bootstrapping.
BUD/FORM: Budesonide/formoterol Turbuhaler, TIO: Tiotropium HandiHaler, PBO: Placebo, CI: Confidence interval.
a Excluding antibiotics. The corresponding table for the sub-analysis, which includes antibiotics in the definition of a severe exac-
erbation can be found in the online appendix.
Nordic CEA of adding ICS/LABA to LAMA in COPD 1715from the base-case under the different scenarios for each
country. In total, 16 tornado diagrams (by country, by
perspective and including vs. excluding antibiotics) were
constructed, which show qualitatively similar results. The
Swedish societal perspective including antibiotics (Fig. 3) is
presented as an example of the results from this analysis.Table 5 Incremental cost-effectiveness ratios of BUD/FORM þ
Societal perspective
Excluding
antibiotics
Incl
ant
Denmark, DKK (V) Dominant Dom
Finland, V 174 149
Norway Dominant Dom
Sweden, SEK (V) Dominant Dom
The effectiveness measure used was severe exacerbations avoided.
BUD/FORM: Budesonide/formoterol Turbuhaler, TIO: Tiotropium HanAll 16 tornado diagrams are presented in the online
appendix.
Sensitivity analyses indicated that results are overall
robust and that most of the tested scenarios have only
minor effects on the ICER estimates. From the societal
perspective, the variables with the largest effect on theTIO relative to PBO þ TIO.
Healthcare perspective
uding
ibiotics
Excluding
antibiotics
Including
antibiotics
inant 1580 (212) 1449 (195)
307 281
inant Dominant Dominant
inant 1573 (165) 1342 (141)
dihaler, PBO: Placebo.
Figure 1 Cost-effectiveness scatter plots of BUD/FORM þ TIO relative to PBO þ TIO.
1716 R. Nielsen et al.ICERs were hospitalisations (cost, frequency, length) and
employment rates for all four countries.Discussion
The above analysis has shown that BUD/FORM þ TIO
compared with PBO þ TIO from both societal and health-
care perspectives in the Nordic countries improves clinical
outcomes at a low cost level or even at reduced costs over a
3-month time horizon. Results incorporating a societal
perspective provided an ICER of V174 in Finland for BUD/
FORM þ TIO compared with PBO þ TIO while BUD/
FORM þ TIO was the dominant treatment option in
Denmark, Norway and Sweden. A sub-analysis incorporating
antibiotic treatment in the definition of a severe exacer-
bation was shown to decrease ICERs by 8e15%. Sensitivity
analyses revealed that results were overall robust, with
parameters related to hospitalisation and employment rate
being most influential.
There is no officially established WTP (for avoided ex-
acerbations) with which to compare the estimated ICERs of
our analysis. Instead, comparisons were made with WTP
and/or ICERs from other published studies. However, one
should be careful when comparing ICERs across studies as
treatment alternatives, subject pools, resources costed,
perspective used, study designs and inputs may differ
considerably.
The only other analysis to have estimated the cost
effectiveness of BUD/FORM þ TIO is the previous CEA basedon the CLIMB trial [24]. As mentioned, that analysis used a
WTP of V600 and found probabilities of BUD/FORM þ TIO
being cost effective of 96%, 83% and 74% from Australian,
Canadian and Swedish healthcare perspectives, respec-
tively. The corresponding probabilities in the present
analysis (healthcare perspective without antibiotics) using
the WTP of V600 (DKK 4468; NOK 4804; SEK 5725) were 73%,
74%, 86% and 77% in Denmark, Finland, Norway and Swe-
den, respectively. One reason why BUD/FORM þ TIO might
have a higher probability of being cost effective in Australia
than in the Nordic countries is the higher hospitalisation
cost in Australia relative to the cost of BUD/FORM.
Other studies have estimated the cost effectiveness (all
measuring the incremental cost per exacerbation avoided)
of alternative triple and monotherapies in COPD. Based on
a 52-week trial, Najafzadeh et al. (2008) [21] estimated the
cost effectiveness of adding the fixed combination of flu-
ticasone/salmeterol (FLU/SAL) to TIO for COPD from a Ca-
nadian healthcare perspective. Exacerbations were defined
as events requiring treatment with steroids/antibiotics.
The ICER of FLU/SAL þ TIO was estimated at CAN$6510 per
exacerbation avoided, which was not deemed cost effec-
tive. Potential explanations for the higher ICER compared
with the current analysis include the higher maintenance
costs and the smaller relative reduction in the exacerbation
rate. For example, FLU/SAL þ TIO was shown to reduce
exacerbations by about 13% (from 1.56 per year to 1.35 per
year) whereas BUD/FORM þ TIO in CLIMB was found to
reduce severe exacerbations by about 62% (from 0.29 to
0.11 per three months, see Table 2). These differences in
Figure 2 Cost-effectiveness acceptability curves.
Nordic CEA of adding ICS/LABA to LAMA in COPD 1717effectiveness percentages may be due to differences in
healthcare systems and patient populations etc., and are
provided purely as potential explanations for the different
cost-effectiveness results.Figure 3 One-way sensitivity analyses results for SwedenOostenbrink et al. (2004) [22] and Rutten-van Mo¨lken
et al. (2007) [23] estimated the cost effectiveness of
monotherapies (ipratropium vs TIO and roflumilast vs PBO,
respectively) and, as such, are not directly comparable tobased on the societal perspective including antibiotics.
1718 R. Nielsen et al.the present analysis. Oostenbrink et al. [22] found an in-
cremental cost per exacerbation avoided of V667 from a
Dutch healthcare perspective and reported probabilities of
being cost effective using a WTP of V2000. Rutten-van
Mo¨lken et al. (2007) [23] found a cost per (severe or mod-
erate) exacerbation avoided of V2356 from a UK societal
perspective and of V1755 from the healthcare perspective
and used WTP thresholds of V5000 and V50,000.
While cost-effectiveness results cannot easily be
compared across studies because effectiveness, costs and
definitions vary, it can be noted that the incremental costs
per severe exacerbation avoided in the present analysis
were all considerably smaller than those mentioned above.
Also, the other studies used long time horizons compared
with that of 3 months in the CLIMB study. Applying the
lowest of the WTPs from the above-mentioned studies,
V2000, to the results of the present analysis yielded
probabilities of BUD/FORM being cost effective of 99e100%
for the two perspectives across the four Nordic countries.
COPD is a chronic disease, so ideally economic evalua-
tions of different treatments should have a lifetime
perspective. Extrapolation of the results was not carried
out beyond the 3-month clinical trial as this may lead to
increased uncertainty in the estimates. One potential
advantage of basing the analysis on a short trial is the low
(and similar across treatments, 7.9% in BUD/FORM þ TIO
and 8.5% in PBO þ TIO) discontinuation rate [20], which
facilitates comparison and may reduce selection biases.
While some studies define severe exacerbations as hos-
pitalisations only, the broader definition of a severe exac-
erbation used in this present analysis is indeed in line with
many clinical studies performed to date, and was based on
the CLIMB clinical trial parameters. In addition to the
economic evaluations mentioned above, a number of ex-
amples of previous studies incorporating systemic GCS as
part of the definition of exacerbations can be found in the
published literature [56e58].
Economic evaluations often use quality-adjusted life
years (QALYs) as an effectiveness measure to more pre-
cisely capture effects on the patient’s health status. In the
CLIMB trial, health status was assessed using St George’s
Respiratory Questionnaire e COPD (SGRQ-C), which, unlike
the European Quality of Life e 5 Dimensions (EQ-5D), is not
a utility measure. Therefore, it could not be used directly
to calculate QALY values. Based on the UK’s National
Institute for Health and Clinical Excellence’s (NICE)
recommendation of not mapping SGRQ to EQ-5D [59], QALYs
were not estimated for this present analysis even though a
measure of health-related quality of life would have
enhanced the comparability of these results with other
studies in different disease areas. Note, that by purely
estimating the cost per severe exacerbation avoided, the
present analysis ignores the positive effects of adding BUD/
FORM to TIO on health-related quality of life. In particular,
the CLIMB trial showed that BUD/FORM þ TIO, relative to
PBO þ TIO, improved SGRQ-C scores and led to rapid and
sustained improvements in lung function, (overall and
morning) symptoms and the ability to perform morning
activities [20].
In the CLIMB trial, antibiotics were not included in the
definition of exacerbation, but data, as well as the reasons
stated by the investigator for the antibiotic use, werecollected. Antibiotics are used in the management of ex-
acerbations in not just Nordic and international guidelines
[18,29e32], but also in CLIMB as 86% of the patients had
been treated with antibiotics at their last exacerbation
before entering the study. In the trial, the numbers of
COPD-related prescriptions of antibiotics were 31 (n Z 27)
and 52 (n Z 48) in the BUD/FORM þ TIO and PBO þ TIO
groups, respectively [20]. Therefore, a sub-analysis of the
CEA included antibiotics in the definition of exacerbation,
which is not unheard of in clinical trials [60,61]. The effect
of including antibiotics in the definition of an exacerbation
on the results was not clear ex ante. It could be that
including antibiotics would turn otherwise separate treat-
ments into overlapping treatments, thereby reducing the
number of exacerbations in either treatment arm while
increasing costs. The analysis showed that the cost effec-
tiveness of BUD/FORM þ TIO was robust to including anti-
biotics in the definition of an exacerbation and even
decreased ICERs by 8e15%.
Some limitations in conducting this present analysis
should be highlighted in order to help with the interpreta-
tion of these results. Firstly, the CLIMB study was not
designed to prospectively gather data on healthcare uti-
lisation and sick-leave costs. As a result, costs associated
with severe exacerbations were applied retrospectively in
this analysis. As the CLIMB study was not powered to show
national differences in severe exacerbations or healthcare
utilisation, it was not possible to perform country-specific
sub-analyses due to the small number of patients and se-
vere exacerbations.
It should also be acknowledged within this present
analysis that Sweden was the only country represented in
terms of patients from actual research sites involved in the
CLIMB trial. However, the main cost driver in COPD in
general, and in this study in particular, was severe exac-
erbations. Given the similar genetic background and de-
mographics of patients and similarities in healthcare
systems within these four Nordic countries, it is likely that
severe exacerbation rates would not differ much across the
countries.
The present analysis included some data that were not
collected as part of the CLIMB trial. No information on GP
consultations was collected, and employment rates were
based on the findings from an epidemiological study in
Sweden [38] (36% of COPD patients aged <65 years in
Sweden were in full- or part-time employment and 22% of
patients with severe COPD were employed). However, the
sensitivity analysis showed that results were robust to
changes in the GP consultation assumptions. Assumptions
regarding indirect costs (particularly sick leave due to
COPD) were made to estimate results from a societal
perspective. Sick leave was assumed to occur only on days
when patients received treatment for severe exacerbations
and patients were thus assumed to resume work immedi-
ately after ending treatment. As it was not recorded
whether exacerbations occurred when patients would
otherwise have been working, the cost per day was
assumed to be the annual labour compensation divided by
365.25 instead of dividing by the number of annual work-
days. Applying the cost per workday instead would have
increased the indirect cost per day and would have made
BUD/FORM þ TIO even more cost effective, as indicated by
Nordic CEA of adding ICS/LABA to LAMA in COPD 1719the one-way sensitivity analysis. Indirect costs arising from
caregivers, productivity losses from early retirement and
presenteeism (i.e. reduced work productivity) were not
included in the analysis. Taken together, these limitations
may mean that the true indirect costs were under-
estimated. In contrast, some argue that the HCA over-
estimates indirect costs as, for example, co-workers may
be able to cover for sick colleagues. However difficult they
are to estimate, there is no doubt that indirect costs are
important and will be even more important given ageing
populations and raising of retirement ages [62].
A degree of uncertainty exists as to the external validity
of our results outside the setting of a clinical randomised
trial. The close monitoring in randomised controlled trials
itself might be considered part of a “treatment” strategy.
Furthermore, other studies have suggested that both
exacerbation rates and healthcare utilisation are higher in
clinical trials, than in population-based studies. One sug-
gested reason is that clinical trials often recruit patients
from hospital clinics and that these patients are in worse
condition than the average patient in the overall popula-
tion. For example, Nielsen et al. (2011) [63] compared
hospital-recruited patients with COPD patients in the gen-
eral population and, although the authors adjusted for
disease severity, education, gender, smoking habits, co-
morbidities and exacerbations, there was a noticeable
difference in costs between these two groups. If this
applied to the current study, the cost-effectiveness results
would be different than those anticipated with a
population-based study sample of COPD patients and the
difference would be similar to the one-way sensitivity an-
alyses relating to exacerbation rates. The same problem
would, of course, apply to any other clinical study with a
hospital-recruited setting.
As would be expected, there was a degree of variation in
terms of unit costs between the four countries; for
example, the cost of an ER visit (Table 4). Even though unit
costs differed somewhat across countries, conclusions from
the CEA were quite similar. Norway was the only country
where treatment with BUD/FORM þ TIO was the dominant
option versus PBO þ TIO under all scenarios. This can, to
some degree, be explained by high hospitalisation costs
relative to the acquisition cost of BUD/FORM. Finland was
the only country in which treatment with BUD/FORM was
not dominant from any perspective. This can partly be
explained by the low relative cost of hospitalisation in
Finland.Conclusion
By utilising the clinical findings from the CLIMB trial, this
analysis indicates that BUD/FORM þ TIO represents a clin-
ical benefit to patients and an economic benefit to
healthcare providers and society for the treatment of COPD
patients eligible for ICS/LABA combination therapy in
Denmark, Finland, Norway and Sweden. In particular, BUD/
FORM þ TIO was the dominant treatment option in
Denmark, Norway and Sweden, and had an incremental cost
per severe exacerbation avoided of V174 in Finland from a
societal perspective excluding antibiotics. Sensitivity
analysis was performed and supported the robustness of thefinding that, based on the CLIMB trial, BUD/FORM when
added to TIO has a high probability of being cost effective
in each of the four countries.Conflicts of interest
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